

# The 2017 Bethesda System for Reporting Thyroid Cytopathology

Edmund S. Cibas<sup>1</sup> and Syed Z. Ali<sup>2</sup>

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting system for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. There is a choice of two different names for some of the categories. A laboratory should choose the one it prefers and use it exclusively for that category. Synonymous terms (e.g., AUS and FLUS) should not be used to denote two distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the “benign” category to virtually 100% for the “malignant” category, and, in the 2017 revision, the malignancy risks have been updated based on new (post 2010) data. As a function of their risk associations, each category is linked to updated, evidence-based clinical management recommendations. The recent reclassification of some thyroid neoplasms as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has implications for the risk of malignancy, and this is accounted for with regard to diagnostic criteria and optional notes. Such notes can be useful in helping guide surgical management.

**Keywords:** thyroid, cytopathology, fine-needle aspiration, terminology, Bethesda, follicular neoplasm, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), molecular testing

## Introduction

WITH ITS INCEPTION, The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized reporting system with a limited number of diagnostic categories for thyroid fine-needle aspiration (FNA) specimens. Using TBSRTC, cytopathologists can communicate their interpretations to the referring physician in terms that are succinct, unambiguous, and clinically useful (1–3).

TBSRTC has been widely adopted in the United States and in many places worldwide and has been endorsed by the American Thyroid Association (4). It has improved communication and provided a uniform template for sharing data among investigators. Since its acceptance in clinical practice, however, questions have arisen over the proper use of the diagnostic categories, the associated risks of malignancy, and the appropriate management. By 2016, the time had come to consider revisions. The 2017 revision described herein was inspired by new data and new developments in the field of thyroid pathology: revised guidelines for the management of

patients with thyroid nodules (4), the introduction of molecular testing as an adjunct to cytopathologic examination, and the reclassification of the noninvasive follicular variant of papillary thyroid carcinoma as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (5). Much of the groundwork for this revision was laid down by a symposium entitled “The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC): Past, Present, and Future” at the 2016 International Congress of Cytology in Yokohama, Japan. Preparations for the symposium began 12 months earlier with the designation of a steering group and the appointment of an international panel of 16 cytopathologists and an endocrinologist, whose task was to review and summarize the published literature in English since the introduction of TBSRTC.

The symposium, moderated by Drs. Syed Ali and Philippe Vielh, took place on May 30, 2016, and the discussions and recommendations from the symposium have been summarized in a publication by Pusztaszeri *et al.* (6). Based on the panel’s recommendation, the six original general categories

This article is being published jointly in *Thyroid* and *Journal of the American Society of Cytopathology*.

<sup>1</sup>Departments of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.

<sup>2</sup>Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.

(“nondiagnostic/unsatisfactory” [ND/UNS], “benign,” “atypia of undetermined significance/follicular lesion of undetermined significance” [AUS/FLUS], “follicular neoplasm/suspicious for a follicular neoplasm” [FN/SFN], “suspicious for malignancy” [SUS], and “malignant”) have been retained in the 2017 revision, and a revised atlas is in press, with updated and expanded chapters devoted to these categories and refined definitions, morphologic criteria, and explanatory notes (7).

### Format of the Report

For clarity of communication, the 2017 BSRTC continues to recommend that each report begin with a general diagnostic category. Because they are more ambiguous and less clearly descriptive, numerical designations alone (e.g., “Bethesda III”) are discouraged for the purposes of cytologic reporting, although the numerical designations may be used in conjunction with the category name, for example “atypia of undetermined significance (Bethesda III).”

The six general diagnostic categories are unchanged and are shown in upper case in Table 1. Some categories have two alternative names. A laboratory should choose the one it prefers and use it exclusively for that category. Synonymous terms (e.g., AUS and FLUS) should not be used to denote two

distinct interpretations. Each of the categories has an implied cancer risk (ranging from 0% to 3% for the benign category to virtually 100% for the malignant category) that links it to an evidence-based clinical management guideline (Table 2).

For some of the general categories, some degree of subcategorization can be informative and is often appropriate (see Table 1). Additional descriptive comments (beyond such subcategorization) are optional and are left to the discretion of the cytopathologist.

Notes and recommendations are not required but can be useful in certain circumstances, particularly if the cytomorphic features raise the possibility of NIFTP. Some laboratories, for example, may wish to state the risk of malignancy (ROM) associated with the general category, based on its own data or those found in the literature.

Table 2 shows revised risks of malignancy (ROM) based on data since 2010. NIFTP has added a wrinkle in this regard by excluding the noninvasive follicular variant of papillary thyroid carcinoma from the list of thyroid carcinomas. NIFTP is, nonetheless, a “surgical disease”—surgery is necessary for these nodules—and Table 2 shows “ROMs” calculated two ways: when NIFTP is not considered a malignancy, and when NIFTP is still included among the “carcinomas.” The higher risk estimates arguably have more clinical relevance because they are defined for surgical disease.

TABLE 1. THE 2017 BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: RECOMMENDED DIAGNOSTIC CATEGORIES

<b>I. NONDIAGNOSTIC OR UNSATISFACTORY</b>
Cyst fluid only
Virtually acellular specimen
Other (obscuring blood, clotting artifact, etc.)
<b>II. BENIGN</b>
Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc.)
Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context
Consistent with granulomatous (subacute) thyroiditis
Other
<b>III. ATYPIA OF UNDETERMINED SIGNIFICANCE or FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE</b>
<b>IV. FOLLICULAR NEOPLASM or SUSPICIOUS FOR A FOLLICULAR NEOPLASM</b>
Specify if Hürthle cell (oncocytic) type
<b>V. SUSPICIOUS FOR MALIGNANCY</b>
Suspicious for papillary carcinoma
Suspicious for medullary carcinoma
Suspicious for metastatic carcinoma
Suspicious for lymphoma
Other
<b>VI. MALIGNANT</b>
Papillary thyroid carcinoma
Poorly differentiated carcinoma
Medullary thyroid carcinoma
Undifferentiated (anaplastic) carcinoma
Squamous-cell carcinoma
Carcinoma with mixed features (specify)
Metastatic carcinoma
Non-Hodgkin lymphoma
Other

Adapted with permission from Ali and Cibas (7).

### Nondiagnostic or Unsatisfactory

Every thyroid FNA should be evaluated for specimen adequacy. Inadequate samples are reported as “nondiagnostic” (ND) or “unsatisfactory” (UNS). Examples include specimens with obscuring blood, poor cell preservation, and an insufficient sample of follicular cells. For a thyroid FNA specimen to be satisfactory for evaluation (and benign), at least six groups of benign follicular cells are required, each group composed of at least 10 cells. The minimum requirement for group size allows one to determine (by the evenness of the nuclear spacing) whether it represents a fragment of a macrofollicle.

Given that the great majority of ND/UNS nodules prove to be benign, one may question whether the criteria for adequacy are too stringent. Lowering the required number of follicular cells would save many patients a repeat FNA. Preliminary data suggest that doing so would substantially reduce ND/UNS interpretations without significantly impacting the false-negative rate (8,9). There is no consensus on a lower number, however, and therefore the criteria have been retained, with the understanding that this is an evolving area that would benefit from more evidence.

The 2017 BSRTC reinforces several exceptions to the numerical requirement of benign follicular cells. Any specimen that contains abundant colloid is adequate (and benign), even if six groups of follicular cells are not identified: a sparsely cellular specimen with abundant colloid is, by implication, a predominantly macrofollicular nodule and therefore almost certainly benign. Whenever a specific diagnosis (e.g., lymphocytic thyroiditis) can be rendered, and whenever there is any significant atypia, the specimen is, by definition, adequate for evaluation.

Specimens that consist only of cyst contents (macrophages) are ND/UNS. The significance (and clinical value) of a ND/UNS, “cyst contents only” result depends in large part

TABLE 2. THE 2017 BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: IMPLIED RISK OF MALIGNANCY AND RECOMMENDED CLINICAL MANAGEMENT

Diagnostic category	Risk of malignancy if NIFTP $\neq$ CA (%)	Risk of malignancy if NIFTP = CA (%)	Usual management <sup>a</sup>
Nondiagnostic or unsatisfactory	5–10	5–10	Repeat FNA with ultrasound guidance
Benign	0–3	0–3	Clinical and sonographic follow-up
Atypia of undetermined significance or follicular lesion of undetermined significance	6–18	~ 10–30	Repeat FNA, molecular testing, or lobectomy
Follicular neoplasm or suspicious for a follicular neoplasm	10–40	25–40	Molecular testing, lobectomy
Suspicious for malignancy	45–60	50–75	Near-total thyroidectomy or lobectomy <sup>b,c</sup>
Malignant	94–96	97–99	Near-total thyroidectomy or lobectomy <sup>c</sup>

Adapted with permission from Ali and Cibas (7).

<sup>a</sup>Actual management may depend on other factors (e.g., clinical, sonographic) besides the FNA interpretation.

<sup>b</sup>Some studies have recommended molecular analysis to assess the type of surgical procedure (lobectomy vs. total thyroidectomy).

<sup>c</sup>In the case of “suspicious for metastatic tumor” or a “malignant” interpretation indicating metastatic tumor rather than a primary thyroid malignancy, surgery may not be indicated.

NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; CA, carcinoma; FNA, fine-needle aspiration.

on sonographic correlation. If the nodule is entirely cystic, with no worrisome sonographic features, an endocrinologist might proceed as if it were a benign result. On the other hand, it might be clinically unsatisfactory if the sonographic features are worrisome and the endocrinologist is not convinced that the sample is representative.

The ROM for an ND/UNS interpretation is difficult to calculate because most ND/UNS nodules are not resected. Among surgically excised nodules initially reported as ND/UNS, the malignancy rate is 9–32%. Surgically resected nodules, however, are a selected subset that were either repeatedly ND/UNS or had worrisome clinical/sonographic features or both. Thus, surgically resected ND/UNS nodules overrepresent malignancies compared to the entire cohort of ND nodules. A reasonable extrapolation of the overall ROM is 5–10% (Table 2) (4).

A repeat aspiration with ultrasound guidance is recommended for cytologically ND/UNS nodules and is diagnostic in most cases, but some nodules remain persistently ND/UNS. Excision is considered for persistently ND/UNS nodules.

In the past, it was often recommended that the patient with an ND/UNS cytology wait three months before a repeat FNA, but this delay often causes patient anxiety. It was reasoned that a transient follicular cell atypia induced by the inflammation that results from a recent FNA might confound interpretation, but a pair of studies does not support this assumption (10,11). The ATA guidelines now state that there is no need to wait several months before repeating the FNA (4).

Unless specified as ND/UNS, the FNA is considered adequate for evaluation; an explicit statement of adequacy remains optional.

### Benign

The 2017 BSRTC has essentially made no changes to the usage, definition, criteria, or usual management association for this category. Data continue to support a very low false-negative rate (<3%).

### Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance

This category has two alternative names. A laboratory should choose the one it prefers and use it exclusively when criteria are fulfilled for this category. AUS and FLUS are therefore synonyms and should not be used to denote two distinct interpretations. It is worth pointing out that, of the two, AUS is more versatile; FLUS applies only to *follicular lesions* of undetermined significance and cannot be used if the cells are not clearly follicular in origin (e.g., lymphoid, parafollicular, parathyroid, etc.).

AUS/FLUS has been studied extensively since the advent of TBSRTC, but calculating the ROM associated with this interpretation has been challenging. Because only a minority of AUS/FLUS cases undergo excision, estimating the ROM based on histologic follow-up alone overestimates the ROM due to selection bias: AUS/FLUS nodules (much like Benign and ND/UNS nodules) are usually resected only if there are worrisome clinical or sonographic features, an abnormal repeat aspiration result, and/or an abnormal molecular testing result. AUS/FLUS nodules with a benign repeat aspiration and/or a benign molecular test result remain (appropriately) unresected. On the other hand, when calculated using the total number of AUS/FLUS specimens (regardless of surgical follow-up) as the denominator, assuming that unresected nodules are benign, the ROM is underestimated. The actual ROM is between the values obtained using these two different calculations and thus requires extrapolation. It is likely that the ROM of AUS/FLUS has been further overestimated due to publication bias (unexpected/discrepant results are more likely to be published than expected findings) (12).

Although the overall low-risk nature of AUS/FLUS aspirates has been borne out, new (pre-NIFTP) data suggest that the ROM is higher than originally estimated and closer to 10–30% (Table 2). On the other hand, if the risk is recalculated by removing NIFTPs from the tally of malignancies, the risk diminishes to 6–18% because early data suggest that NIFTP constitutes a substantial proportion of the “malignancies” hidden in this category (13,14).

The ROM differs according to the nature of the atypia. The 2017 BSRTC recommends subclassification of the atypia, even though this will not generally affect patient management. Descriptive language such as “cytologic atypia” and “architectural atypia” is preferred (rather than “rule out papillary carcinoma,” etc.) due to its less provoking nature, as follows:

- (i) *Cytologic atypia*. This may take one of several different forms: focal nuclear changes, extensive but mild nuclear changes, atypical cyst lining cells, or “histiocytoid” cells (15–17).
- (ii) *Architectural atypia*. This is often a sparsely cellular sample but one that is comprised mostly of microfollicles.
- (iii) *Cytologic and architectural atypia*. Cytologic atypia and architectural atypia are not mutually exclusive.
- (iv) *Hürthle cell AUS/FLUS*. This is often a sparsely cellular sample comprised exclusively of Hürthle cells. Alternatively, AUS/FLUS may be used for a moderately or markedly cellular sample composed exclusively (or almost exclusively) of Hürthle cells if the clinical setting suggests a benign Hürthle cell nodule, such as in chronic lymphocytic (Hashimoto) thyroiditis or a multinodular goiter.
- (v) *Atypia, not otherwise specified*.

It is good to think of AUS/FLUS as a category of last resort. The original TBSRTC recommended that an effort be made to limit its use to approximately  $\leq 7\%$  of all thyroid FNAs. This proved a difficult challenge for many laboratories, and a more realistic limit might be 10%.

The usual management now includes consideration of molecular testing.

### Follicular Neoplasm or Suspicious for a Follicular Neoplasm

This category likewise has two alternative names. A laboratory should choose the one it prefers and use it exclusively. FN and SFN are synonymous terms and should not be used to denote two distinct interpretations. SFN is preferred by some laboratories because a significant proportion of cases (up to 35%) prove not to be neoplasms but rather hyperplastic proliferations of follicular cells, most commonly those of multinodular goiter (18–22).

The 2017 BSRTC includes a modification to the definition and diagnostic criteria for this category in light of NIFTP. In the original BSRTC, cases that demonstrated the nuclear features of papillary thyroid carcinoma were excluded from this category. The new definition reads as follows: “Follicular-patterned cases with mild nuclear changes (increased nuclear size, nuclear contour irregularity, and/or chromatin clearing) can be classified as FN/SFN so long as true papillae and intranuclear pseudoinclusions are absent; a note that some nuclear features raise the possibility of a follicular variant of papillary thyroid carcinoma (FVPTC) or NIFTP can be included” (7).

If the cytologic features raise the possibility of FVPTC or NIFTP (a predominance of microfollicles and only mild or focal nuclear changes), the following optional note (or something similar) may be useful:

Note: Although the architectural features suggest a follicular neoplasm, some nuclear features raise the possibility of an invasive follicular variant of papillary carcinoma or its recently described indolent counterpart, NIFTP; definitive distinction among these entities is not possible on cytologic material.

This note will apply only to a subset of FN/SFN cases: those with mild nuclear changes.

As with AUS/FLUS, if the ROM for FN/SFN is recalculated by removing NIFTPs from the tally of malignancies, the risk diminishes (see Table 2). Early data suggest that NIFTP constitutes a substantial proportion of the “malignancies” hidden in this category as well (13,14).

The recommended management of a patient with a diagnosis of FN/SFN is surgical excision of the lesion, most often a hemithyroidectomy or lobectomy, but molecular testing may be used to supplement risk assessment rather than proceeding directly to surgery.

### Suspicious for Malignancy

As with AUS/FLUS and FN/SFN, if the ROM for this category (“SUS”) is recalculated by removing NIFTPs from the tally of malignancies, the risk diminishes (see Table 2). Early data suggest that NIFTP constitutes a substantial proportion of the “malignancies” hidden in this category as well (13,14).

Some but not all of the cases in this category raise the possibility of FVPTC or NIFTP. For this subset, the following optional note (or something similar) may be useful (23):

Note: The cytomorphologic features are suspicious for a follicular variant of papillary thyroid carcinoma or its recently described indolent counterpart NIFTP.

This can be useful in guiding the clinical team in the direction of lobectomy rather than thyroidectomy for this subset of SUS cases.

### Malignant

The general category “malignant” is used whenever the cytomorphologic features are conclusive for malignancy. Descriptive comments that follow are used to subclassify the malignancy and summarize the results of special studies, if any.

Based on early studies, NIFTP constitutes only a very small fraction of cases that are interpreted as “malignant.” Nevertheless, the 2017 BSRTC has modified the definition and criteria for cases of papillary thyroid carcinoma that belong in the malignant category. To avoid false-positives due to NIFTP, it suggests limiting use of the malignant category to cases with “classical” features of papillary thyroid carcinoma (true papillae, psammoma bodies, and nuclear pseudoinclusions) (6,23). Nevertheless, it is likely that a small number of malignant cytologic interpretations will be followed by a histologic NIFTP diagnosis, and thus the following optional note may be used when the diagnosis “malignant; papillary thyroid carcinoma” is made:

Note: A small proportion of cases ( $\sim 3\text{--}4\%$ ) diagnosed as malignant and compatible with papillary thyroid carcinoma may prove to be NIFTP on histopathologic examination.

### Highlights of the 2017 BSRTC

The original six categories remain unchanged, but a number of enhancements have been introduced with the 2017 BSRTC:

- (i) The risks of malignancy have been recalculated based on the post-2010 data.
- (ii) The risks of malignancy are shown two ways (see Table 2): first, when NIFTP is not considered a malignancy, and second, when NIFTP is still included among the “carcinomas.” The higher risk estimates may have more clinical relevance because they are defined for surgical disease.
- (iii) The “usual management” of AUS/FLUS and FN/SFN now incorporates the option of molecular testing.
- (iv) The definition and diagnostic criteria for FN/SFN have been revised in light of NIFTP. Cases that demonstrate mild nuclear changes associated with papillary thyroid carcinoma are now included.
- (v) The definition and diagnostic criteria for the papillary thyroid carcinoma subset of the malignant category have been modified to suggest limiting use to cases with “classical” features of papillary thyroid carcinoma.
- (vi) Optional education notes may be used for the subsets of FN/SFN and SUS with cytomorphic features suggestive of FVPTC or NIFTP.
- (vii) An optional education note may be used for “malignant; papillary thyroid carcinoma” cases to acknowledge that a small proportion may prove to be NIFTP.

It is our hope that the 2017 BSRTC will continue to stimulate interest in the improvement of thyroid cytopathologic diagnosis and the betterment of patients with thyroid nodular disease. Subsequent experience, it is expected, will lead to further refinements to this terminology framework.

### Acknowledgments

The authors thank Dr. Erik Alexander for his review of the manuscript and helpful comments.

The authors thank the many individuals who laid the foundation for the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) in 2007 and contributed to the publication of the two monographs (TBSRTC 2010 and TBSRTC II 2018). This includes the organizers and participants of The National Cancer Institute (NCI) Thyroid Fine Needle Aspiration (FNA) State of the Science Conference in Bethesda, Maryland in 2007 and the International Academy of Cytology (IAC)-sponsored special symposium “TBSRTC-Past, Present and Future” at the ICC congress in Yokohama in 2016.

#### *Participants of the NCI Conference (2007) and TBSRTC 2010 Atlas Contributors:*

Andrea Abati, MD (Organizer, NCI Conference); Susan J. Mandel, MD, MPH (Co-moderator, NCI Conference); Zubair W. Baloch, MD, PhD (Committee Chair, Terminology and Morphologic Criteria, NCI Conference).

Pedro Patricio de Agustin, MD, PhD, Erik K. Alexander, MD, Sylvia L. Asa, MD, PhD, Kristen A. Atkins, MD, Manon Auger, MD, Zubair W. Baloch, MD, PhD, Katherine Berzowski, MD, Massimo Bongiovanni, MD, Douglas P. Clark,

MD, Béatrix Cochand-Priollet, MD, PhD, Barbara A. Crothers, DO, Richard M. DeMay, MD, Tarik M. Elsheikh, MD, William C. Faquin, MD, PhD, Armando C. Filie, MD, Pinar Firat, MD, William J. Frable, MD, Kim R. Geisinger, MD, Hossein Gharib, MD, Ulrike M. Hamper, MD, Michael R. Henry, MD, Jeffrey F. Krane, MD, PhD, Lester J. Layfield, MD, Virginia A. LiVolsi, MD, Britt-Marie E. Ljung, MD, Claire W. Michael, MD, Ritu Nayar, MD, Yolanda C. Oertel, MD, Martha B. Pitman, MD, Celeste N. Powers, MD, PhD, Stephen S. Raab, MD, Andrew A. Renshaw, MD, Juan Rosai, MD, Miguel A. Sanchez, MD, Vinod Shidham, MD, Mary K. Sidawy, MD, Gregg A. Staerkel, MD, Edward B. Stelow, MD, Philippe Vielh, MD, PhD, Jerry Waisman, MD, Helen H. Wang, MD, Dr.PH, Grace C. H. Yang, MD, Matthew A. Zarka, MD.

#### *Participants of the IAC-sponsored Thyroid Symposium, Yokohama (2016) and TBSRTC II 2018 Atlas Contributors:*

William C. Faquin, MD, PhD (Group leader, ICC Symposium 2016); Marc Puztaszeri, MD (Lead Panelist, ICC Symposium 2016); Diana Rossi, MD, PhD (Lead Panelist, ICC Symposium 2016); Philippe Vielh, MD, PhD (Co-moderator, ICC Symposium 2016).

Erik K. Alexander, MD, Manon Auger, MD, Zubair W. Baloch, MD, PhD, Justin A. Bishop, MD, Massimo Bongiovanni, MD, Ashish Chandra, MD, Béatrix Cochand-Priollet, MD, PhD, David S. Cooper, MD, Barbara A. Crothers, DO, Tarik M. Elsheikh, MD, William C. Faquin, MD, PhD, Armando C. Filie, MD, Pinar Firat, MD, Mary C. Frates, MD, Hossein Gharib, MD, Michael R. Henry, MD, SoonWon Hong, MD, PhD, Jeffrey F. Krane, MD, PhD, Kennichi Kakudo, MD, PhD, Lester J. Layfield, MD, Virginia A. LiVolsi, MD, Claire W. Michael, MD, Ritu Nayar, MD, Michiya Nishino, MD, Martha B. Pitman, MD, Celeste N. Powers, MD, PhD, Marc Puztaszeri, MD, Gregory W. Randolph, MD, Andrew A. Renshaw, MD, Diana Rossi, MD, PhD, Miguel A. Sanchez, MD, Fernando Schmitt, MD, PhD, Vinod Shidham, MD, Mary K. Sidawy, MD, Gregg A. Staerkel, MD, Edward B. Stelow, MD, Paul A. VanderLaan, MD, PhD, Philippe Vielh, MD, PhD, William H. Westra, MD, PhD, Grace C. H. Yang, MD, Matthew A. Zarka, MD.

### References

1. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* **19**:1159–1165.
2. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. *Am J Clin Pathol* **132**:658–665.
3. Ali SZ, Cibas ES 2009 The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. Springer, New York, NY.
4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L 2016 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **26**:1–133.
5. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal

- G, Mete O, Nikiforova MN, Nose V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA 2016 Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. *JAMA Oncol* **2**:1023–1029.
6. Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K, Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC 2016 The Bethesda System for Reporting Thyroid Cytopathology: proposed modifications and updates for the second edition from an international panel. *Acta Cytol* **60**:399–405.
  7. Ali S, Cibas E 2018 *The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes*. Second edition. Springer, New York, NY.
  8. Renshaw AA 2012 Histologic follow-up of nondiagnostic thyroid fine needle aspirations: implications for adequacy criteria. *Diagn Cytopathol* **40**:E13–15.
  9. Vivero M, Renshaw AA, Krane JF 2017 Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. *Cancer* **125**:534–543.
  10. Singh RS, Wang HH 2011 Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules. *Acta Cytol* **55**:544–548.
  11. Lee HY, Baek JH, Yoo H, Kim JK, Lim MK, Chu YC, Kang YH, Lim JY 2014 Repeat fine-needle aspiration biopsy within a short interval does not increase the atypical cytologic results for thyroid nodules with previously nondiagnostic results. *Acta Cytol* **58**:330–334.
  12. Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, Marti JL 2015 Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. *Surgery* **157**:510–517.
  13. Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA 2015 The impact of non-invasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. *Thyroid* **25**:987–992.
  14. Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW 2016 Impact of re-classifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. *Cancer Cytopathol* **124**:181–187.
  15. Renshaw AA 2002 “Histiocytoid” cells in fine-needle aspirations of papillary carcinoma of the thyroid: frequency and significance of an under-recognized cytologic pattern. *Cancer* **96**:240–243.
  16. Harshan M, Crapanzano JP, Aslan DL, Vazquez MF, Saqi A 2009 Papillary thyroid carcinoma with atypical histiocytoid cells on fine-needle aspiration. *Diagn Cytopathol* **37**:244–250.
  17. Yang GC, Stern CM, Messina AV 2010 Cystic papillary thyroid carcinoma in fine needle aspiration may represent a subset of the encapsulated variant in WHO classification. *Diagn Cytopathol* **38**:721–726.
  18. Yang J, Schnadig V, Logrono R, Wasserman PG 2007 Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. *Cancer* **111**:306–315.
  19. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW 2006 Fine-needle aspiration of follicular lesions of the thyroid. *Diagnosis and follow-up*. *Cytojournal* **3**:9.
  20. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK 2002 Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol* **26**:41–44.
  21. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL, Rosales RF, Weaver AL 1997 Factors that predict malignant thyroid lesions when fine-needle aspiration is “suspicious for follicular neoplasm.” *Mayo Clin Proc* **72**:913–916.
  22. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS 2001 Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. *Thyroid* **11**:271–277.
  23. Krane JF, Alexander EK, Cibas ES, Barletta JA 2016 Coming to terms with NIFTP: a provisional approach for cytologists. *Cancer Cytopathol* **124**:767–772.

Address correspondence to:  
 Edmund S. Cibas, MD  
 Department of Pathology  
 Brigham and Women's Hospital  
 75 Francis Street  
 Boston, MA 02115  
 E-mail: ecibas@bwh.harvard.edu